SecBot SecBot
SECBOTREPLAY Home › Report › VIR

VIR · Phase 3 HDV trial hits endpoint

Vir Biotechnology, Inc. · 8-K filed Nov 9, 2026 at 08:31 ET

At the news

BULLISHIMPACT 6/10

8-K filed Nov 9, 2026 at 08:31 ET

Vir Biotechnology announced positive Phase 3 ECLIPSE 1 topline results for its combination regimen of elebsiran and tobevibart in chronic hepatitis delta, meeting the primary endpoint with a 44% response rate vs 0% in the delayed treatment group (p<0.0001). Expanded Phase 2 SOLSTICE data showed 100% of patients reaching undetectable viremia at Week 96, and an exploratory finite treatment analysis showed all 10 patients who discontinued treatment achieved SVR12. The data were presented at AASLD on November 8, 2026.

  • Phase 3 ECLIPSE 1 primary endpoint met: 44% undetectable virus + ALT normalization at Week 48 vs 0% in delayed treatment group (p<0.0001)
  • Key secondary endpoint: 79% undetectable virus at Week 48 vs 0% (p<0.0001)
  • 100% virologic response (HDV RNA TND or 2 log10 reduction) in active arm vs 0% in control
  • Phase 2 SOLSTICE Week 96: 100% (28/28) of patients on combination therapy reached undetectable viremia

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access